Skip to main content
Deciphera
Deciphera

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • Investors & News
twitter linkedin

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Main Utility

  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • Investors & News
twitter linkedin

02/07/2023

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results

Read More

02/07/2023

Read More
Deciphera
twitter linkedin
contact us

Main navigation

  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • DCC-3116
    • Preclinical Pipeline
    • Expanded Access
  • Our Medicine
    • QINLOCK® (ripretinib)
  • Who We Are
    • Management
    • Board of Directors
  • Join Us
    • Open Positions

Footer Utility

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement

© 2023 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.